A Phase Ib/II, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antineoplastic Activity of CT-707 in Combination With Toripalimab and Gemcitabine in Advanced Pancreatic Cancer
Latest Information Update: 21 Oct 2022
At a glance
- Drugs Conteltinib (Primary) ; Gemcitabine (Primary) ; Toripalimab (Primary)
- Indications Adenocarcinoma; Carcinoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Shouyao Holdings
Most Recent Events
- 17 Oct 2022 New trial record